Dr Reddy's Laboratories (DRL) has received setback from US District Court, New Jersey, regarding palonosetron hydrochloride 0.25 mg/5ml product. The Court issued its opinion that the product infringes certain claims of US Patent Nos 7,947,724, 8,729,094 and 9,066,980, and that the asserted claims of the '094 and '980 patents were not invalid. Helsinn Healthcare filed an infringement claims against DRL's proposed palonosetron product, pursuant to a 'paper' NDA under section 505(b) (2) of the Food, Drug and Cosmetic Act.

A company spokesperson stated “We are disappointed in the decision and intend to pursue an appeal in due course.”

DRL scrip declined in the mornings session on BSE by Rs.20 to Rs.2,890 from its previous day's close of Rs.2910.05. The scrip touched to 52-week lowest level today at Rs.2853.50.